

## CURRICULUM VITAE

**Name:** JUNTARO MATSUZAKI, M.D., Ph.D. 39 years old

**e-mail:** juntaro.matsuzaki@ucsf.edu

### Current Academic Position

#### **Postdoctoral Scholar**

McManus lab, Diabetes Center, UC San Francisco

513 Parnassus Ave, Rm 1047A, UCSF Box 0534 HSW,

San Francisco, CA 94143, United States

### Education

- 3/2013** **Ph. D.** (Dr. of Medical Science), Keio University Graduate School of Medicine  
(Thesis: Biliary findings assist in predicting enlargement of intraductal papillary mucinous neoplasms of the pancreas.)
- 3/2005** **M. D.**, Keio University School of Medicine

### Work Experience

- 9/2019- Present,** Postdoctoral scholar, Diabetes Center, UC San Francisco, CA, USA
- 9/2019- Present,** Adjunct Faculty, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
- 8/2019- Present,** Visiting Researcher, Department of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan
- 4/2019- Present,** Visiting Researcher, Division of Cellular Signaling (Yamamoto Group), National Cancer Center Research Institute, Tokyo, Japan
- 4/2019- 8/2019,** Assistant Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
- 7/2015- 3/2019,** Project Researcher, Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan
- 7/2015- 3/2019,** Adjunct faculty member, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
- 10/2013- 6/2015,** Instructor, Center for Preventive Medicine, Keio University Hospital, Tokyo, Japan
- 4/2013- 9/2013,** GI physician, Division of Gastroenterology, Department of Internal Medicine, Saiseikai Central Hospital, Tokyo, Japan
- 4/2011- 3/2013,** Research Fellow of the Japan Society for the Promotion of Science (DC2)
- 4/2007- 3/2013,** Fellow and PhD student, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

4/2005- 3/2007,

Resident, Saiseikai Yokohamashi-Nanbu Hospital, Yokohama, Japan

### **Specialization/Research interests**

Circulating microRNAs, Extracellular vesicles, Gastroenterology; Cancer cell biology; Bile acid metabolism; Liver and pancreatic regeneration; Barrett's esophagus; *Helicobacter pylori*; Functional GI disorders

### **Awards and Honors**

2018: **Young Investigator Award**, the 15th Korea-Japan Joint Symposium on *Helicobacter* infection

2017: **Director Award**, Young Researchers Seminar, National Cancer Center

2016: **Namiki Award**, the 84th Meeting of Japanese Society of Psychosomatic Medicine on Digestive Diseases

2016: **Poster of Excellence**, United European Gastroenterology Week 2016

2015: **Best Poster Presentation Award**, the 4th Biennial Congress of Asian Neurogastroenterology & Motility Association

2014: **Nice Discussant Award**, the 9th Inflammation Conference in Alimentary Tract

2014: **Best Discussant Award**, the 8th Japan & US Collaboration Conference in Gastroenterology

2014: **Distinguished Abstract Award**, the 1st Federation of Neurogastroenterology and Motility Meeting

2014: **Young Investigator Award**, Keio University School of Medicine Alumni Association

2014: **Travel Grant**, the 4th Asian Pacific Topic Conference

2014: **Oral Presentation Award**, the 4th Asian Pacific Topic Conference

2013: **Publication Award**, the 8th Inflammation Conference in Alimentary Tract

2013: **Best Discussant Award**, the 7th Japan & US Collaboration Conference in Gastroenterology

2013: **Poster of Distinction**, Digestive Disease Week 2013

2012: **Excellent Award**, the 6th Japan & US Collaboration Conference in Gastroenterology

2012: **Young Investigator Award for the most excellent presentation**, the 5th International Gastrointestinal Consensus Symposium

2011: **Nice Discussant Award**, the 6th Inflammation Conference in Alimentary Tract

2011: **Travel Grant**, United European Gastroenterology Week 2011

2011: **Best Participant Award**, the 6th Free Radical Research Conference in Gastroenterology

2010: **Travel Grant**, United European Gastroenterology Week 2010

2009: **Most Excellent Award**, The 2nd Japanese Functional Dyspepsia Conference

2009: **Most Excellent Award**, The 4th Inflammation Conference in Alimentary Tract

### **Grant supports**

1. **JSPS Grant-in-Aid for Scientific Research (C)**. "Identification of circulating microRNAs as biomarkers of early stage pancreatic cancer" 2017-2019: 4,550,000 JPY
2. **JSPS Grant-in-Aid for Young Scientists (B)**. "Function of miR-221/222 for adiponectin signaling in esophageal adenocarcinoma" 2014-2015: 3,770,000 JPY
3. **Takeda Science Foundation Medical Research Promotion Grant (Oncology Area)**. "Evaluation of circulating miR-221/222 as novel tumor biomarkers" 2014-2016: 2,000,000 JPY

4. **Keio Gijuku Academic Development Funds.** "Identification of genetic mutations in *Helicobacter pylori* associated with hosts' dyspepsia symptoms." 2014: 300,000 JPY.
5. **Research Grants for Life Sciences and Medicine, Keio University Medical Science Fund.** "Function of Adiponectin in suppressing esophageal carcinogenesis." 2014: 500,000 JPY
6. **Grant-in-Aid for JSPS Fellows (DC2).** "MicroRNA therapy for Barrett's esophagus and esophageal adenocarcinoma." 2011-2012: 1,300,000 JPY
7. **Keio University Grant-in-Aid for Encouragement of Young Medical Scientists.** "Investigation of oncogenic mechanisms and novel molecular therapeutic target in Barrett's esophagus and esophageal adenocarcinoma." 2010: 250,000 JPY.
8. **Keio University Graduate School Doctoral Student Aid Program.** "MicroRNA dynamics in the transformation of Barrett's esophagus into esophageal adenocarcinoma" 2010: 1,000,000 JPY
9. **Keio University Graduate School Doctoral Student Aid Program.** "Baseline factors associated with the transformation of Barrett's esophagus into esophageal adenocarcinoma" 2008: 2,000,000 JPY

### **Publications**

1. **Matsuzaki J**, Tsugawa H, Suzuki H. Precision medicine approaches to prevent gastric cancer. *Gut Liver* 1121:1-9 (2020)
2. **Matsuzaki J**, Ochiya T. Circulation microRNAs: next-generation cancer detection. *Keio J Med* [Epub ahead of print]
3. Yamamoto Y\*, Kondo S\*, **Matsuzaki J**\*, Esaki M, Okusaka T, Shimada K, Kato K, Aoki Y, Takizawa S, Sakamoto H, Niida S, Takeshita F, Ochiya T. (\*equally contributed to this work) Highly sensitive circulating microRNA panel for the early detection of hepatocellular carcinoma. *Hepatol Commun* 4:284-297 (2020)
4. Asakura K\*, Kadota T\*, **Matsuzaki J**, Yoshida Y, Yamamoto Y, Nakagawa K, Takizawa S, Aoki Y, Sakamoto H, Kato K, Watanabe S, Ochiya T. (\*equally contributed to this work) A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy. *Commun Biol* 3:134 (2020)
5. Katsuda T\*, Hosaka K\*, **Matsuzaki J**, Usuba W, Prieto-Vila M, Yamaguchi T, Tsuchiya A, Terai S, Ochiya T. (\*equally contributed to this work) Transcriptomic dissection of hepatocyte heterogeneity: linking ploidy, zonation, and stem/progenitor cell characteristics *Cell Mol Gastroenterol Hepatol* 9:161-183 (2020)
6. Sudo K, Kato K, **Matsuzaki J**, Takizawa S, Aoki Y, Shoji H, Iwasa S, Honma Y, Takashima A, Sakamoto H, Naka T, Sekine S, Boku N, Ochiya T. Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab. *Jpn J Clin Oncol* 50:114-121 (2020)
7. Horibe M, Iwasaki E, Nakagawa A, **Matsuzaki J**, Minami K, Machida Y, Tamagawa H, Takimoto Y, Ueda M, Katayama T, Kawasaki S, Matsushita M, Seino T, Fukuhara S, Kanai T. Efficacy and safety of immediate oral intake in patients with mild acute pancreatitis: a randomized controlled trial. *Nutrition* 74:110724 (2020)
8. Horibe M, Iwasaki E, Bazerbachi F, Kaneko T, **Matsuzaki J**, Minami K, Fukuhara S, Masaoka T, Hosoe N, Ogura Y, Namiki S, Hosoda Y, Ogata H, Kanai T. The Horibe gastrointestinal bleeding prediction score: a simple score for triage decision-making management in patients with suspected upper gastrointestinal bleeding. *Gastrointest Endosc* [Epub ahead of print]
9. Noda-Narita S, Shimomura A, Tanabe Y, Kawauchi J, **Matsuzaki J**, Takizawa S, Shimizu C, Tamura K, Ochiya T.

Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs. *BMJ Support Palliat Care* [Epub ahead of print]

10. Tadokoro H, Hirayama A, Kudo R, Hasebe M, Yoshioka Y, **Matsuzaki J**, Yamamoto Y, Sugimoto M, Soga T, Ochiya T. Adenosine leakage from perforin-burst extracellular vesicles inhibits perforin secretion by cytotoxic T-lymphocytes. *PLOS ONE* 15:e0231430 (2020)
11. **Matsuzaki J\***, Tsugawa H\*, Kashiwazaki Y, Mori H, Yamamoto Y, Kameyama N, Masaoka T, Kanai T, Suzuki H. (\*equally contributed to this work) Neutrophil-activating protein polymorphism of *Helicobacter pylori* determines the host risk of dyspepsia. *Cell Mol Gastroenterol Hepatol* 8:295-297 (2019)
12. **Matsuzaki J**, Suzuki H, Shimoda M, Mori H, Fukuhara S, Miyoshi S, Masaoka T, Iwao Y, Kanai Y, Kanai T. Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma *United European Gastroenterol J* 7, 250-260 (2019).
13. Asano N\*, **Matsuzaki J\***, Ichikawa M, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Yoshida A, Kobayashi E, Tanzawa Y, Morioka H, Matsumoto M, Nakamura M, Kondo T, Kato K, Tsuchiya N, Kawai A, Ochiya T. (\*equally contributed to this work) A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. *Nat Commun* 10:1299 (2019).
14. Urabe F\*, **Matsuzaki J\***, Yamamoto Y, Kimura T, Hara T, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Egawa S, Fujimoto H, Ochiya T. (\*equally contributed to this work) Large-scale circulating miRNA profiling for the liquid biopsy of prostate cancer *Clin Cancer Res* 25, 3016-3025 (2019).
15. Sonoda T\*, **Matsuzaki J\***, Yamamoto Y, Aoki Y, Takizawa S, Niida S, Ochiya T. (\*equally contributed to this work) Serum miRNA-based risk prediction for stroke. *Stroke* 50, 1510-1518 (2019).
16. Ohno M\*, **Matsuzaki J\***, Kawauchi J, Aoki Y, Miura J, Takizawa S, Kato K, Sakamoto H, Matsushita Y, Takahashi M, Miyakita Y, Ichimura K, Narita Y, Ochiya T. (\*equally contributed to this work) Diagnostic ability of serum microRNA classification in diffuse glioma: a retrospective comprehensive analysis with case-control study. *JAMA Netw Open* 2, e1916953 (2019).
17. Yokoi A\*, **Matsuzaki J\***, Yamamoto Y, Tate K, Yoneoka Y, Shimizu H, Uehara T, Ishikawa M, Takizawa S, Aoki Y, Kato K, Kato T, Ochiya T. (\*equally contributed to this work) Serum microRNA profile enables preoperative diagnosis for uterine leiomyosarcoma. *Cancer Sci* 110, 3718-3726 (2019).
18. Shiino S, **Matsuzaki J**, Shimomura A, Kawauchi J, Takizawa S, Sakamoto H, Aoki Y, Yoshida M, Tamura K, Kinoshita T, Kitagawa Y, Ochiya T. The development of a prediction model using serum microRNAs for evaluating axillary lymph node metastasis in breast cancer. *Clin Cancer Res* 15, 1817-1827 (2019).
19. Katsuda T, **Matsuzaki J**, Yamaguchi T, Yamada Y, Prieto-Vila M, Hosaka K, Takeuchi A, Saito Y, Ochiya T. Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes. *Elife* 8, e47313 (2019).
20. Yamaguchi T, **Matsuzaki J**, Katsuda T, Saito Y, Saito H, Ochiya T. Generation of functional human hepatocytes in vitro: current status and future prospects. *Inflamm Regen* 39, 13 (2019).
21. Tsugawa H, Mori H, **Matsuzaki J**, Sato A, Saito Y, Imoto M, Suematsu M, Suzuki H. CAPZA1 determines the risk of gastric carcinogenesis by inhibiting *Helicobacter pylori* CagA-degraded autophagy. *Autophagy* 15, 242-258 (2019).

22. Sudo K, Kato K, **Matsuzaki J**, Boku N, Abe S, Saito Y, Daiko H, Takizawa S, Aoki Y, Sakamoto H, Niida S, Takeshita F, Fukuda T, Ochiya T. Development and validation of an esophageal squamous cell carcinoma detection model by large-scale microRNA profiling *JAMA Netw Open* 2, e194573 (2019).
23. Yokoyama S, Yoshinaga T, **Matsuzaki J**, Suzuki H. A randomized, double-blind, placebo-controlled study to evaluate the efficacy of the teprenone in patients with Alzheimer's disease. *J Alzheimers Dis* 71, 1187-1199 (2019).
24. Satomi-Tsushita N\*, Shimomura A\*, **Matsuzaki J**, Yamamoto Y, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Kato K, Shimizu C, Ochiya T, Tamura K. (\*equally contributed to this work) Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. *PLOS ONE* 14:e0222024 (2019)
25. Chuma M, Toyoda H, **Matsuzaki J**, Saito Y, Kumada T, Tada T, Kanaoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Takeda K, Kunisaki C, Kazushi N, Fukuda H, Kondo M, Nozaki A, Maeda S, Sakamoto N. Circulating miRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. *Hepato Res* 49, 810-822 (2019).
26. Mori H, Suzuki H, **Matsuzaki J**, Masaoka T, Kanai T. 10-year trends in *Helicobacter pylori* eradication rates by sitafloxacin-based third-line rescue therapy. *Digestion* 1193, 1-7 (2019).
27. Usuba W\*, Urabe F\*, Yamamoto Y\*, **Matsuzaki J**, Sasaki H, Ichikawa M, Takizawa S, Aoki Y, Niida S, Kato K, Egawa S, Chikaraishi T, Fujimoto H, Ochiya T. (\*equally contributed to this work) Circulating microRNA panels for specific and early detection in bladder cancer. *Cancer Sci* 110, 408-419 (2019).
28. Tsugawa H, Kato C, Mori H, **Matsuzaki J**, Kameyama K, Saya H, Suematsu M, Suzuki H. Cancer stem-cell marker CD44v9-positive cells arise from *Helicobacter pylori*-infected CAPZA1-overexpressing cells. *Cell Mol Gastroenterol Hepatol* 8:319-334 (2019).
29. Sato J, Shimomura A, Kawauchi J, **Matsuzaki J**, Yamamoto Y, Takizawa S, Sakamoto H, Ohno M, Narita Y, Ochiya T, Tamura K. Brain metastasis-related microRNAs in patients with advanced breast cancer. *PLOS ONE* 14:e0221538 (2019).
30. Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Sugiyama Y, **Matsuzaki J**, Uchida R, Yoshikawa N, Furukawa R, Saito H. Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. *Cell Rep* 27, 1265-1276.e4 (2019).
31. **Matsuzaki J**, Suzuki H, Togawa K, Yamane T, Mori H, Komori T, Masaoka T, Kanai T. Burden of impaired sleep quality on work productivity in functional dyspepsia. *United European Gastroenterol J* 6, 398-406 (2018).
32. **Matsuzaki J**, Ochiya T. Extracellular microRNAs and oxidative stress in liver injury: a systematic mini review. *J Clin Biochem Nutr* 61, 1-8 (2018).
33. Yokoi A\*, **Matsuzaki J**\*, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda S, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T. Integrated extracellular microRNA profiling for ovarian cancer screening. *Nat Commun* 9:4319 (2018). (\*equally contributed to this work)
34. Suzuki H, **Matsuzaki J**. Gastric cancer: evidence boosts *H. pylori* eradication. *Nat Rev Gastroenterol Hepatol* 15, 458-460 (2018).
35. Suzuki H, **Matsuzaki J**. *Helicobacter pylori* eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk. *Gut* 67, 2071-2072 (2018).
36. Mori H, Suzuki H, **Matsuzaki J**, Masaoka T, Kanai T. Acquisition of double mutation in *gyrA* caused high resistance

- to sitafloxacin in *Helicobacter pylori* after unsuccessful eradication with sitafloxacin-containing regimens. *United European Gastroenterol J* 6, 391-397 (2018).
37. Horibe M, Ogura Y, **Matsuzaki J**, Kaneko T, Yokota T, Okawa O, Nakatani Y, Iwasaki E, Nishizawa T, Hosoe N, Masaoka T, Yahagi N, Namiki S, Kanai T. Absence of high risk stigmata predicts good prognosis even in severely anemic patients with suspected upper gastrointestinal bleeding. *United European Gastroenterol J* 6, 684-690 (2018).
  38. Miyoshi S, Tsugawa H, **Matsuzaki J**, Hirata K, Mori H, Saya H, Kanai T, Suzuki H. Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression. *Anticancer Res* 38, 6163-6170 (2018).
  39. **Matsuzaki J**, Suzuki H. Circulating microRNAs as potential biomarkers to detect transformation of Barrett's oesophagus to oesophageal adenocarcinoma. *BMJ Open Gastroenterol* 4, e000160 (2017).
  40. **Matsuzaki J**, Ochiya T. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. *Int J Clin Oncol* 22, 413-420 (2017).
  41. Hironaka-Mitsuhashi A, **Matsuzaki J**, Takahashi RU, Yoshida M, Nezu Y, Yamamoto Y, Shiino S, Kinoshita T, Ushijima T, Hiraoka N, Shimizu C, Tamura K, Ochiya T. A tissue microRNA signature that predicts breast cancer recurrence in young women. *PLoS One* 12, e0187638 (2017).
  42. Mori H, Suzuki H, **Matsuzaki J**, Masaoka T, Kanai T. Antibiotic resistance and *gyrA* mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for *Helicobacter pylori* in penicillin allergic patients. *United European Gastroenterol J* 5, 796-804 (2017).
  43. Mori H, Suzuki H, **Matsuzaki J**, Taniguchi K, Shimizu T, Yamane T, Masaoka T, Kanai T. Gender difference of gastric emptying in healthy volunteers and patients with functional dyspepsia. *Digestion* 95, 72-78 (2017).
  44. Fukuhara S, Masaoka T, Nishimura S, Nakamura M, **Matsuzaki J**, Tsugawa H, Miyoshi S, Mori H, Kawase S, Shibata S, Okano H, Kanai T, Suzuki H. Enteric glial dysfunction evoked by apolipoprotein E deficiency contributes to delayed gastric emptying. *Dig Dis Sci* 62, 3359-3369 (2017).
  45. **Matsuzaki J**, Hayashi R, Arakawa T, Ueno F, Kinoshita Y, Joh T, Takahashi S, Naito Y, Fukudo S, Chan F, Hahn KB, Kachitorn U, Fock KM, Syam AF, Rani AA, Sollano JD, Zhu Q, Fujiwara Y, Kubota E, Kataoka H, Tokunaga K, Uchiyama K, Suzuki H, IGICS Study Group. Questionnaire-based survey on diagnostic and therapeutic endoscopies and *H. pylori* eradication for elderly patients in East Asian countries. *Digestion* 93, 93-102 (2016).
  46. **Matsuzaki J**, Suzuki H, Masaoka T, Tanaka K, Mori H, Kanai T. Influence of regular exercise on gastric emptying in healthy men: a pilot study. *J Clin Biochem Nutr* 59, 130-133 (2016).
  47. Togawa K, **Matsuzaki J**, Fukushima Y, Suzaki F, Kasugai K, Nishizawa T, Naito Y, Hayakawa T, Kamiya T, Andoh T, Yoshida H, Tokura Y, Nagata H, Kobayakawa M, Mori M, Kato K, Hosoda H, Takebayashi T, Miura S, Uemura N, Joh T, Hibi T, Suzuki H. Association of baseline plasma des-acyl ghrelin level with the response to rikkunshito in patients with functional dyspepsia. *J Gastroenterol Hepatol* 31, 334-341 (2016).
  48. Mori H, Suzuki H, **Matsuzaki J**, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Masaoka T, Kanai T. Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for *Helocobacter pylori* strains containing the *gyrA* mutation. *Helocobacter* 21, 286-294 (2016).
  49. Mori H, Suzuki H, **Matsuzaki J**, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Masaoka T, Nishizawa T, Kanai T. Rifabutin based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for

- Helicobacter pylori* eradication: a pilot study. *United European Gastroenterol J* 4, 380-387 (2016).
50. Lee SY, Masaoka T, Han HS, **Matsuzaki J**, Hong MJ, Fukuhara S, Choi HS, Suzuki H. A prospective study on symptom generation according to spicy food intake and TRPV1 genotypes in functional dyspepsia patients. *Neurogastroenterol Motil* 28:1401-1408 (2016).
  51. Takayama M, Hirose H, Shimizu R, Makino K, **Matsuzaki J**, Takata N, Shiomi E, Yoshida T, Inoue N, Iwao Y, Sugino Y. Relationship between bone mineral density and metabolic biomarkers in postmenopausal women who underwent a comprehensive health check-up. *Ningen Dock Int* 3:7-12 (2016).
  52. Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, **Matsuzaki J**, Ono M, Takeshita F, Niida S, Shimizu C, Fujiwara Y, Kinoshita T, Kenji T, Ochiya T. Novel combination of serum microRNA for detecting breast cancer in the early stage. *Cancer Sci* 107:326-334 (2016).
  53. Horibe M, Kaneko T, Yokogawa N, Yokota T, Okawa O, Nakatani Y, Ogura Y, **Matsuzaki J**, Iwasaki E, Hosoe N, Masaoka T, Inadomi JM, Suzuki H, Kanai T, Namiki S. A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: a prospective cohort study. *Dig Liver Dis* 48:1180-1186 (2016).
  54. **Matsuzaki J**, Suzuki H, Kobayakawa M, Inadomi JM, Takayama M, Makino K, Iwao Y, Sugino Y, Kanai T. Association of visceral fat area, smoking, and alcohol consumption with reflux esophagitis and Barrett's esophagus in Japan. *PLoS One* 10: e0133865 (2015).
  55. **Matsuzaki J**, Suzuki H: Role of microRNAs-221/222 in digestive systems. *J Clin Med* 4:1566-1577 (2015).
  56. Tsugawa H, Mori H, **Matsuzaki J**, Masaoka T, Hirayama T, Nagasawa H, Sakakibara Y, Suematsu M, Suzuki H. Nordihydroguaiaretic acid disrupts the antioxidant ability of *Helicobacter pylori* through the repression of SodB activity in vitro. *BioMed Res Int* 2015:734548 (2015).
  57. **Matsuzaki J**, Suzuki H: MicroRNAs in Barrett's esophagus: Future prospects. *Front Genet* 5:69 (2014).
  58. Fukuhara S, **Matsuzaki J**, Tsugawa H, Masaoka T, Miyoshi S, Mori H, Fukushima Y, Yasui M, Kanai T, Suzuki H. Mucosal expression of aquaporin-4 in the stomach of histamine type 2 receptor knockout mice and *Helicobacter pylori*-infected mice. *J Gastroenterol Hepatol* 29 Suppl 4:53-59 (2014).
  59. Suzuki H, **Matsuzaki J**, Fukushima Y, Suzaki F, Kasugai K, Nishizawa T, Naito Y, Hayakawa T, Kamiya T, Andoh T, Yoshida H, Tokura Y, Nagata H, Kobayakawa M, Mori M, Kato K, Hosoda H, Takebayashi T, Miura S, Uemura N, Joh T, Hibi T, Tack J: Randomised clinical trial: rikkunshito in the treatment of functional dyspepsia - a multi-centre, double-blind, randomised, placebo-controlled study. *Neurogastroenterol Motil* 26:950-961 (2014).
  60. Suzuki H, **Matsuzaki J**, Masaoka T, Inadomi JM: Greater loss of productivity among Japanese workers with gastro-esophageal reflux disease (GERD) symptoms that persist vs resolve on medical therapy. *Neurogastroenterol Motil* 26:764-771 (2014).
  61. Nishizawa T, Suzuki H, **Matsuzaki J**, Kanai T, Yahagi N: Propofol versus traditional sedative agents for endoscopic submucosal dissection. *Dig Endosc* 26:701-706 (2014).
  62. **Matsuzaki J**, Suzuki H, Tsugawa H, Watanabe M, Hossain S, Arai E, Saito Y, Sekine S, Akaike T, Kanai Y, Mukaiho KI, Auwerx J, Hibi T: Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. *Gastroenterology* 145:1300-1311 (2013).
  63. **Matsuzaki J**, Suzuki H, Okuda S, Tanimoto A, Asakura K, Fukuhara S, Okada S, Hirata K, Mori H, Masaoka T,

- Higuchi H, Hozawa S, Kuribayashi S, Takebayashi T, Hibi T: Biliary findings assist in predicting enlargement of intraductal papillary mucinous neoplasms of the pancreas. *Clin Gastroenterol Hepatol* 11:548-554 (2013).
64. Suzuki H, **Matsuzaki J**, Okada S, Hirata K, Fukuhara S, Hibi T: Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. *United European Gastroenterol J* 1:175-183 (2013).
65. Hirata K, Suzuki H, **Matsuzaki J**, Masaoka T, Saito Y, Nishizawa T, Iwasaki E, Fukuhara S, Okada S, Hibi T: Improvement of reflux symptom related quality of life after *Helicobacter pylori* eradication therapy. *J Clin Biochem Nutr* 52:172-178 (2013).
66. Hirata K, Suzuki H, Imaeda H, **Matsuzaki J**, Tsugawa H, Nagano O, Asakura K, Saya H, Hibi T: CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. *Br J Cancer* 109:379-386 (2013).
67. Saito Y, Suzuki H, Imaeda H, **Matsuzaki J**, Hirata K, Tsugawa H, Hibino S, Kanai Y, Saito H, Hibi T: The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. *Int J Cancer* 132:1751-1760 (2013).
68. Suzuki H, Kusunoki H, Kamiya T, Futagami S, Yamaguchi Y, Nishizawa T, Iwasaki E, **Matsuzaki J**, Takahashi S, Sakamoto C, Haruma K, Joh T, Asakura K, Hibi T: Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. *United European Gastroenterol J* 1:445-452 (2013).
69. **Matsuzaki J**, Suzuki H, Nishizawa T, Hirata K, Tsugawa H, Saito Y, Okada S, Fukuhara S, Hibi T: Efficacy of sitafloxacin-based rescue therapy for *Helicobacter pylori* after failures of first- and second-line therapies. *Antimicrob Agents Chemother* 56:1643-1645 (2012).
70. **Matsuzaki J**, Suzuki H, Asakura K, Fukushima Y, Inadomi JM, Takebayashi T, Hibi T: Classification of functional dyspepsia based on concomitant bowel symptoms. *Neurogastroenterol Motil* 24:325-e164 (2012).
71. **Matsuzaki J**, Suzuki H, Fukushima Y, Hirata K, Fukuhara S, Okada S, Hibi T: High frequency of overlap between functional dyspepsia and overactive bladder. *Neurogastroenterol Motil* 24:821-827 (2012).
72. Fukushima Y, Suzuki H, **Matsuzaki J**, Kiyosue A, Hibi T: Efficacy of solifenacin on irritable bowel syndrome with diarrhea: open-label prospective pilot trial. *J Neurogastroenterol Motil* 18:317-323 (2012).
73. Suzuki H, **Matsuzaki J**: Are solifenacin and ramosetron really ideal to treat irritable bowel syndrome?: author's reply. *J Neurogastroenterol Motil* 18:459 (2012).
74. Tsugawa H, Suzuki H, **Matsuzaki J**, Hirata K, Hibi T: FecA1, a bacterial iron transporter, determines the survival of *Helicobacter pylori* in the stomach. *Free Radic Biol Med* 52:1003-1010 (2012).
75. Mogami S, Suzuki H, Fukuhara S, **Matsuzaki J**, Kangawa K, Hibi T: Reduced ghrelin production induced anorexia after rat gastric ischemia and reperfusion. *Am J Physiol Gastrointest Liver Physiol* 302:G359-364 (2012).
76. Saito Y, Suzuki H, Tsugawa H, Imaeda H, **Matsuzaki J**, Hirata K, Hosoe N, Nakamura M, Mukai M, Saito H, Hibi T: Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to *Helicobacter pylori* eradication. *PLoS One* 7:e47396 (2012).
77. Saito Y, Suzuki H, Taya T, Nishizawa M, Tsugawa H, **Matsuzaki J**, Hirata K, Saito H, Hibi T: Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs. *Biochem Biophys Res Commun* 426:33-37 (2012).
78. Tsugawa H, Suzuki H, Saya H, Hatakeyama M, Hirayama T, Hirata K, Nagano O, **Matsuzaki J**, Hibi T: Reactive



oxygen species-induced autophagic degradation of *Helicobacter pylori* CagA is specifically suppressed in cancer stem-like cells. *Cell Host Microbe* 12:764-777 (2012).

79. **Matsuzaki J**, Suzuki H, Asakura K, Saito Y, Hirata K, Takebayashi T, Hibi T: Etiological difference between ultrashort- and short-segment Barrett's esophagus. *J Gastroenterol* 46:332-338 (2011).
80. Suzuki H, **Matsuzaki J**, Hibi T: Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for *Helicobacter pylori* eradication? *Expert Rev Clin Pharmacol* 4:579-582 (2011).
81. Suzuki H, **Matsuzaki J**, Hibi T: What is the difference between *Helicobacter pylori*-associated dyspepsia and functional dyspepsia? *J Neurogastroenterol Motil* 17:124-130 (2011).
82. Suzuki H, **Matsuzaki J**, Hibi T: Ghrelin and oxidative stress in gastrointestinal tract. *J Clin Biochem Nutr* 48:122-125 (2011).
83. Nishizawa T, Suzuki H, **Matsuzaki J**, Muraoka H, Tsugawa H, Hirata K, Hibi T: *Helicobacter pylori* resistance to rifabutin in the last 7 years. *Antimicrob Agents Chemother* 55:5374-5375 (2011).
84. Saito Y, Suzuki H, Tsugawa H, Suzuki S, **Matsuzaki J**, Hirata K, Hibi T: Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in *Helicobacter pylori*-infected mice. *Gastroenterology* 140:189-198 (2011).
85. Tsugawa H, Suzuki H, Satoh K, Hirata K, **Matsuzaki J**, Saito Y, Suematsu M, Hibi T: Two amino acids mutation of ferric uptake regulator determines *Helicobacter pylori* resistance to metronidazole. *Antioxid Redox Signal* 14:15-23 (2011).
86. Nishizawa T, Suzuki H, Tsugawa H, Muraoka H, **Matsuzaki J**, Hirata K, Ikeda F, Takahashi M, Hibi T: Enhancement of amoxicillin resistance after unsuccessful *Helicobacter pylori* eradication. *Antimicrob Agents Chemother* 55:3012-3014 (2011).
87. Tsugawa H, Suzuki H, Muraoka H, Ikeda F, Hirata K, **Matsuzaki J**, Saito Y, Hibi T: Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in *Helicobacter pylori*. *Biochem Biophys Res Commun* 404:656-660 (2011).
88. **Matsuzaki J**, Suzuki H, Asakura K, Saito Y, Hirata K, Takebayashi T, Hibi T: Gallstones increase the prevalence of Barrett's esophagus. *J Gastroenterol* 45:171-178 (2010).
89. **Matsuzaki J**, Suzuki H, Iwasaki E, Yokoyama H, Sugino Y, Hibi T: Serum lipid levels are positively associated with non-erosive reflux disease, but not with functional heartburn. *Neurogastroenterol Motil* 22:965-970, e251 (2010).
90. **Matsuzaki J**, Suzuki H, Minegishi Y, Sugai E, Tsugawa H, Yasui M, Hibi T: Acid suppression by proton pump inhibitors enhances aquaporin-4 and KCNQ1 expression in gastric fundic parietal cells in mouse. *Dig Dis Sci* 55:3339-3348 (2010).
91. **Matsuzaki J**, Suzuki H, Tsugawa H, Nishizawa T, Hibi T: Homology model of the DNA gyrase enzyme of *Helicobacter pylori*, a target of quinolone-based eradication therapy. *J Gastroenterol Hepatol* 25 Suppl 1:S7-10 (2010).
92. Suzuki S, Suzuki H, Horiguchi K, Tsugawa H, **Matsuzaki J**, Takagi T, Shimojima N, Hibi T: Delayed gastric emptying and disruption of the interstitial cells of Cajal network after gastric ischaemia and reperfusion. *Neurogastroenterol Motil* 22:585-593, e126 (2010).
93. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, Saito Y, **Matsuzaki J**, Hibi T: Contribution of efflux

pumps to clarithromycin resistance in *Helicobacter pylori*. *J Gastroenterol Hepatol* 25 Suppl 1:S75-79 (2010).

94. Imaeda H, Hosoe N, Nakamizo H, Kashiwagi K, Suzuki H, Saito Y, Suganuma K, Ida Y, **Matsuzaki J**, Iwasaki E, Iwao Y, Ogata H, Hibi T: Clinical results of observation of the upper gastrointestinal tract by transgastrostomic endoscopy using an ultrathin endoscope. *J Gastroenterol Hepatol* 25:1850-1854 (2010).
95. Saito Y, Suzuki H, Tsugawa H, Nakagawa I, **Matsuzaki J**, Kanai Y, Hibi T: Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. *Oncogene* 28:2738-2744 (2009).